SecBot SecBot
6-K ·Filed Jul 15, 2026

RDY

DR REDDYS LABORATORIES LTD
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001575872-26-000504
Notable filing: 6-K
Actionable Insight ▼ Bearish

Monitor Dr. Reddy's Q1 FY27 earnings (due in ~2 weeks) for inventory write-down details and updated semaglutide revenue guidance. Track progress on root-cause analysis and re-validation timelines; any extension beyond September would further pressure the stock. Competitors like Sandoz and Aspen may accelerate their own GLP-1 launches, increasing competitive risk.

DirectionBearish
Confidencehigh
Horizonweeks

Drug in focus

RDY drug pipeline →

semaglutide

◆ Mixed Named in this 6-K
Impact
Phase
Approved - Generic
Time to market
Already launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.
Next catalyst
None dated

What to watchWatch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.77
T+0 close · Jul 15, 2026 · via day close
Latest settled
−4.46%
T+60 · $12.20
Vs SPY
−7.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $12.77entry
  2. T+1 · 4mo ago −0.55%α −0.01% · $12.70
  3. T+5 · 4mo ago −10.88%α −9.90% · $11.38
  4. T+20 · 3mo ago −2.98%α −5.32% · $12.39
  5. T+60 · 6w ago −4.46%α −7.00% · $12.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's disclosed a manufacturing impurity issue in the scale-up of its semaglutide injection API, causing a halt in commercial supply for approximately three months. The company now expects to supply only 6-7 million pens in FY27 (down from prior guidance of ~12 million), with no patient safety impact or recall. This is a material negative for near-term revenue from its key GLP-1 product.

Key Facts

  • Impurity (degradation) detected in finished drug product from a scale-up validation batch of semaglutide injection API.
  • Commercial supply halted until process is fixed and re-validated; expected resumption late October/early November 2026.
  • FY27 semaglutide pen guidance revised to 6-7 million pens (from prior ~12 million), with supply concentrated in Q3-Q4.
  • No patient safety impact, no recall of previously supplied product, and no impact on oral semaglutide or existing regulatory filings.
  • Potential write-down of inventory held at partner OneSource; no penalty clauses in partner agreements but down payments may be renegotiated.

Financial Impact

FY27 semaglutide injection revenue cut by roughly 40-50% vs prior expectations; potential inventory write-down of undisclosed amount; no penalty fees but possible renegotiation of customer advances.

revenueinventoryguidance

Risk Factors

  • Further delay if re-validation fails again, pushing commercial supply into 2027.
  • Loss of market share to competitors (Sandoz, Aspen, Torrent) during the supply gap.
  • Potential partner renegotiations or termination if supply reliability is questioned.
  • Regulatory scrutiny if impurity issue escalates, though no agency notification required currently.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000504
Document: 0001575872-26-000504-index.html0001575872-26-000504
Document: 0001575872-26-000504.txt0001575872-26-000504

Track record

73 reports on RDY

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 6 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026